E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
patients with non-small cell lung cancer in stage IIB / IV |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this open-label, single arm Phase II trial is to explore the efficacy of BIBW 2992 defined by the objective response rate (CR, PR) as determined by the RECIST criteria (R01-0754) in patients with advanced NSCLC Stage IIIB or IV whose tumours harbour activating mutations within exon 18 to exon 21 of the EGFR receptor, in patients with mutations in the HER2/neu receptor and in patients with EGFR FISH positive tumours with no EGFR mutations. |
|
E.2.2 | Secondary objectives of the trial |
•Disease control (CR, PR, SD) determined by RECIST (R01-0754) •Progression-free survival time •Pharmacokinetic parameters of BIBW 2992 •Safety of BIBW 2992 as indicated by intensity and incidence of adverse events, graded according to NCI CTCAE Version 3.0 (R04-0474) especially skin reactions and GI adverse events
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1.Patients with pathologically confirmed diagnosis of NSCLC Stage IIIB (with pleural effusion) or Stage IV; histopathological classification of adeno- or bronchoalveolar carcinoma (BAC). 2.non smokers patients or patients having smoked less than 15 pack years and who stopped smoking for at least one year before diagnosis (for cohorts 1 and 2) 3.Presence of activating mutation(s) in exon 18 to exon 21 of the EGFR or HER2-neu-receptor confirmed by direct DNA sequencing of NSCLC tumour tissue (see Section 3.3.3) or increased copy number of the EGFR gene as determined by FISH analysis 4.Prior treatment: •Cohort 1: progressive disease following therapy with first line EGFR TKI following diagnosis of activating mutation •Cohort 2: No prior EGFR TKI, up to three lines of chemotherapy (including adjuvant) •Cohort 3: no restrictions 5.Patients with at least one tumour lesion that can accurately be measured by computed tomography (CT) or magnetic resonance imaging (MRI) in at least one dimension with longest diameter to be recorded as ≥20 mm using conventional techniques or ≥10 mm with spiral CT scan. 6.Male or female patient aged ≥18 years 7.Life expectancy of at least three (3) months. 8.Written informed consents that is consistent with ICH-GCP guidelines. 9.Eastern Cooperative Oncology Group (ECOG, R01-0787) performance score 0, 1 or 2.
|
|
E.4 | Principal exclusion criteria |
1.More than three (3) prior cytotoxic chemotherapy treatment regimens for relapsed or metastatic NSCLC, except for patients with HER2-neu mutations who may have received any prior therapy 2.Chemo-, hormone- (other than Megace® or steroids required for maintenance non-cancer therapy) or immunotherapy within the past 4 weeks or within less than four half-lives of the previous drug prior to treatment with the trial drug and/or persistence of toxicities of prior anticancer therapies which are deemed to be clinically relevant. 3.Brain metastases, which are symptomatic; patients with treated, asymptomatic brain metastases are eligible with stable brain disease for at least four (4) weeks without the requirement for steroids or anti-epileptic therapy. 4.Significant or recent acute gastrointestinal disorders with diarrhoea as a major symptom e.g., Crohn’s disease, malabsorption, or CTCAE Grade >2 diarrhoea of any etiology at baseline 5.Patients who have any other life-threatening illness or organ system dysfunction, which in the opinion of the investigator, would either compromise patient safety or interfere with the evaluation of the safety of the test drug 6.Other malignancies diagnosed within the past five (5) years (other than non melanomatous skin cancer and in situ cervical cancer). 7.Radiotherapy within the past 2 weeks prior to treatment with the trial drug 8.Patients with any serious active infection (i.e., requiring IV antibiotic, antifungal, or antiviral agents). 9.Patients with known HIV, active hepatitis B or active hepatitis C (see Section 5.2.3). 10.Known or suspected active drug or alcohol abuse. 11.Women of child-bearing potential or men who are able to father a child unwilling to use a medically acceptable method of contraception during the trial. 12.Pregnancy or breast feeding. 13.Patient unable to comply with the protocol. 14.History of clinically significant or uncontrolled cardiac disease, including congestive heart failure, angina, myocardial infarction, arrhythmia, including New York Heart Association (NYHA) functional classification of 3. 15.Cardiac left ventricular function with resting ejection fraction of less than 50% measured by multigated blood pool imaging of the heart (MUGA scan) or Echocardiogram. 16.Absolute neutrophil count (ANC) less than 1500/mm³. 17.Platelet count less than 100 000 / mm³. 18.Bilirubin greater than 1.5 mg / dl (>26 µmol / L, SI unit equivalent). 19.Aspartate amino transferase (AST) or alanine amino transferase (ALT) greater than three times the upper limit of normal (if related to liver metastases greater than five times the upper limit of normal). 20.Serum creatinine greater than 1.5 times of the upper normal limit
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint will be objective response (CR, PR) as determined by the RECIST (R01-0754) criteria. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 4 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The clinical trial will be considered completed as soon as the last patient has completed the last visit, Follow up visits included. In case the trial is stopped by the sponsor for safety reasons, patients will not continue treatment with the trial drug.
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 19 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 19 |
E.8.9.2 | In all countries concerned by the trial days | 0 |